SAN DIEGO, April 7, 2026 /PRNewswire/ — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”) today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
